RESTORE extension study demonstrates fully maintained initial ...

RESTORE extension study demonstrates fully maintained initial vision gains with an average of 13.9 ranibizumab 0.5mg injections over three years for patients with visual impairment due to DMO (VI-DMO)[i] New data for Lucentis? (ranibizumab) has demonstrated improvement in visual acuity achieved with individualised treatment after one year is maintained for up to three years on average in patients with VI-DMO, with fewer injections in years two and three compared to the first year and no additional or new safety risks identified1...

Realtime Related Tweets

invalid username or userid in get_avatar

Source: http://www.kiefit.com/Health_Fitness/lucentis-ranibizumab-for-treating-visual-impairment-due-to-diabetic-macular-oedema-study-shows-new-evidence/

between two ferns ihop statins chardon sean young juan pablo montoya free pancakes at ihop